FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310784126> ?p ?o ?g. }

• W4310784126 endingPage "103" @default.
• W4310784126 startingPage "95" @default.
• W4310784126 abstract "The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamide and androgen-deprivation therapy. In this substudy, relugolix, an oral gonadotropin-releasing hormone antagonist, was evaluated in combination with apalutamide.The aim of this study was to evaluate whether the approved standard maintenance dose of relugolix in combination with apalutamide sustains castrate testosterone levels (< 50 ng/dL).Twelve patients with HR-LPC who met all the main study criteria were included in the substudy. Patients received relugolix monotherapy for 2 weeks (loading dose [360 mg] at Day - 14 then 120 mg/day daily until Day - 1), then daily relugolix (120 mg) with apalutamide (240 mg) from Day 1 to Day 28. Endpoints were rate of maintained castration (testosterone < 50 ng/dL) through Day 28 (primary) and safety (secondary).All 12 patients received relugolix and apalutamide and achieved castrate testosterone levels after 2-week relugolix monotherapy (median testosterone 348.5 ng/dL and 8.7 ng/dL at Days - 14 and - 1). All 11 patients who had testosterone measured at Day 28 maintained castrate testosterone (median 10.0 ng/dL) without relugolix dose adjustment. Treatment-emergent adverse events (TEAEs) occurred in nine patients during relugolix monotherapy and in eight patients during relugolix + apalutamide coadministration. Hot flush was the most common TEAE reported, in six and four patients, respectively.Relugolix administered at approved standard doses concurrently with apalutamide was effective in maintaining castrate testosterone levels in HR-LPC without new safety signals.NCT04523207, 21 August 2020.The Apa-RP study evaluates the combination of apalutamide with drugs that lower male sex hormones for reducing the risk of prostate cancer recurrence. Patients in this study had their prostate gland surgically removed and were at high risk for disease recurrence. Relugolix, a newly approved oral drug for advanced prostate cancer, lowers blood testosterone (the primary male sex hormone) and, in combination with apalutamide, may reduce the risk of prostate cancer recurrence. The Apa-RP substudy goal was to test whether relugolix lowers blood testosterone and maintains these low levels when administered with apalutamide. Researchers looked at the testosterone levels of 12 patients with early prostate cancer who received standard doses of relugolix alone for 2 weeks followed by apalutamide and relugolix for an additional 28 days. Testosterone was measured before and after 2 weeks of relugolix treatment, and then again 28 days after apalutamide was added. All 12 substudy patients achieved low testosterone levels (< 50 ng/dL) after 2 weeks of relugolix treatment. Testosterone was measured at Day 28 of relugolix + apalutamide treatment in 11 patients, all of whom maintained low testosterone without adjustment of their relugolix dose. Adverse effects were consistent with those previously reported for each drug when administered alone. All 12 patients completed the substudy and moved onto the main study, the longer-term results of which will be reported in the future. In summary, relugolix administered at the same time as apalutamide was effective in maintaining low testosterone levels in patients with prostate cancer, without any new safety concerns." @default.
• W4310784126 created "2022-12-17" @default.
• W4310784126 creator A5001669965 @default.
• W4310784126 creator A5002966804 @default.
• W4310784126 creator A5016024490 @default.
• W4310784126 creator A5020614716 @default.
• W4310784126 creator A5028488821 @default.
• W4310784126 creator A5046899948 @default.
• W4310784126 creator A5051153455 @default.
• W4310784126 creator A5064230008 @default.
• W4310784126 creator A5088518998 @default.
• W4310784126 date "2022-12-06" @default.
• W4310784126 modified "2023-09-25" @default.
• W4310784126 title "Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases" @default.
• W4310784126 cites W1878336561 @default.
• W4310784126 cites W2071879495 @default.
• W4310784126 cites W2084637523 @default.
• W4310784126 cites W2144312415 @default.
• W4310784126 cites W2160217483 @default.
• W4310784126 cites W2395721717 @default.
• W4310784126 cites W2410578203 @default.
• W4310784126 cites W2792086148 @default.
• W4310784126 cites W2947014957 @default.
• W4310784126 cites W2969494549 @default.
• W4310784126 cites W3014348002 @default.
• W4310784126 cites W3032046986 @default.
• W4310784126 cites W3083310601 @default.
• W4310784126 cites W3093310001 @default.
• W4310784126 cites W3134592109 @default.
• W4310784126 cites W3158318954 @default.
• W4310784126 cites W4212895767 @default.
• W4310784126 cites W4213329576 @default.
• W4310784126 cites W4286296857 @default.
• W4310784126 doi "https://doi.org/10.1007/s11523-022-00932-8" @default.
• W4310784126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36472728" @default.
• W4310784126 hasPublicationYear "2022" @default.
• W4310784126 type Work @default.
• W4310784126 citedByCount "2" @default.
• W4310784126 countsByYear W43107841262023 @default.
• W4310784126 crossrefType "journal-article" @default.
• W4310784126 hasAuthorship W4310784126A5001669965 @default.
• W4310784126 hasAuthorship W4310784126A5002966804 @default.
• W4310784126 hasAuthorship W4310784126A5016024490 @default.
• W4310784126 hasAuthorship W4310784126A5020614716 @default.
• W4310784126 hasAuthorship W4310784126A5028488821 @default.
• W4310784126 hasAuthorship W4310784126A5046899948 @default.
• W4310784126 hasAuthorship W4310784126A5051153455 @default.
• W4310784126 hasAuthorship W4310784126A5064230008 @default.
• W4310784126 hasAuthorship W4310784126A5088518998 @default.
• W4310784126 hasBestOaLocation W43107841261 @default.
• W4310784126 hasConcept C121608353 @default.
• W4310784126 hasConcept C126322002 @default.
• W4310784126 hasConcept C126894567 @default.
• W4310784126 hasConcept C197934379 @default.
• W4310784126 hasConcept C2778313021 @default.
• W4310784126 hasConcept C2779279991 @default.
• W4310784126 hasConcept C2779322244 @default.
• W4310784126 hasConcept C2779466945 @default.
• W4310784126 hasConcept C2780192828 @default.
• W4310784126 hasConcept C2781406297 @default.
• W4310784126 hasConcept C61367390 @default.
• W4310784126 hasConcept C71924100 @default.
• W4310784126 hasConceptScore W4310784126C121608353 @default.
• W4310784126 hasConceptScore W4310784126C126322002 @default.
• W4310784126 hasConceptScore W4310784126C126894567 @default.
• W4310784126 hasConceptScore W4310784126C197934379 @default.
• W4310784126 hasConceptScore W4310784126C2778313021 @default.
• W4310784126 hasConceptScore W4310784126C2779279991 @default.
• W4310784126 hasConceptScore W4310784126C2779322244 @default.
• W4310784126 hasConceptScore W4310784126C2779466945 @default.
• W4310784126 hasConceptScore W4310784126C2780192828 @default.
• W4310784126 hasConceptScore W4310784126C2781406297 @default.
• W4310784126 hasConceptScore W4310784126C61367390 @default.
• W4310784126 hasConceptScore W4310784126C71924100 @default.
• W4310784126 hasIssue "1" @default.
• W4310784126 hasLocation W43107841261 @default.
• W4310784126 hasLocation W43107841262 @default.
• W4310784126 hasLocation W43107841263 @default.
• W4310784126 hasOpenAccess W4310784126 @default.
• W4310784126 hasPrimaryLocation W43107841261 @default.
• W4310784126 hasRelatedWork W1967410728 @default.
• W4310784126 hasRelatedWork W2001194010 @default.
• W4310784126 hasRelatedWork W2054241287 @default.
• W4310784126 hasRelatedWork W2093197441 @default.
• W4310784126 hasRelatedWork W2119114732 @default.
• W4310784126 hasRelatedWork W2127440557 @default.
• W4310784126 hasRelatedWork W2249178546 @default.
• W4310784126 hasRelatedWork W2402249956 @default.
• W4310784126 hasRelatedWork W2421909196 @default.
• W4310784126 hasRelatedWork W3150909901 @default.
• W4310784126 hasVolume "18" @default.
• W4310784126 isParatext "false" @default.
• W4310784126 isRetracted "false" @default.
• W4310784126 workType "article" @default.